{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:51:55Z","timestamp":1794469915975,"version":"4.9.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.041","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T19:21:09Z","timestamp":1660245669000},"page":"285-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria"],"prefix":"10.1016","volume":"173","author":[{"given":"James","family":"Larkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-2885","authenticated-orcid":false,"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Lance","family":"Cowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-6391","authenticated-orcid":false,"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-9124","authenticated-orcid":false,"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"M\u00e1rquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-2158","authenticated-orcid":false,"given":"Anna Marie","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-1685","authenticated-orcid":false,"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"De la Cruz-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Fecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-6633","authenticated-orcid":false,"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Askelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.06.041_bib1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III of IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.06.041_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.06.041_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.06.041_bib4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.06.041_bib5","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.06.041_bib6","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition Cancer Staging Manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2022.06.041_bib7","doi-asserted-by":"crossref","first-page":"djaa008","DOI":"10.1093\/jnci\/djaa008","article-title":"Melanoma prognosis: accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition","volume":"112","author":"Bajaj","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.06.041_bib8","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAFV600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.06.041_bib9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","volume":"116","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.06.041_bib10","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.06.041_bib11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-B and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2022.06.041_bib12","article-title":"Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab","volume":"8","author":"Samlowski","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.06.041_bib13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","article-title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Michielin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.06.041_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.06.041_bib15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.06.041_bib16","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","article-title":"Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines","volume":"28","author":"Romano","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.06.041_bib17","doi-asserted-by":"crossref","unstructured":"Weber J, Mandala M, Del Vecchio M, et\u00a0al. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III\/IV melanoma: a randomised, double-blind, phase 3 trial (CheckMate 238). Presented at the European Society of Medical Oncology (ESMO) Congress; September 8\u201312, 2017; Madrid, Spain. Abstract LBA8_PR.","DOI":"10.1093\/annonc\/mdx440.048"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:34:46Z","timestamp":1762342486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":17,"alternative-id":["S0959804922003926"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.041","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}